Beginning July 1 millions of Medicare beneficiaries may gain access to some of the most talked-about weight-loss medications in America through a new Medicare GLP-1 Bridge Program.
Obesity is one of the nation’s fastest-growing health challenges and is linked to numerous chronic conditions including heart disease, stroke, high blood pressure, Type 2 diabetes, sleep apnea, arthritis, and kidney disease. Over the last several years GLP-1 medications such as Wegovy and Zepbound have shown remarkable success in helping patients lose weight while improving overall health outcomes.
According to federal health officials, roughly 40 percent of Medicare beneficiaries meet the medical definition of obesity. With nearly 70 million Americans enrolled in Medicare, that means approximately 28 million seniors and disabled beneficiaries could potentially benefit from obesity treatment.
Until now, however, Medicare generally has not covered these drugs when prescribed solely for weight loss, leaving many beneficiaries unable to afford treatment.
The GLP-1 Bridge Program is available to Medicare beneficiaries enrolled in a Medicare Part D prescription drug plan, including stand-alone Part D plans and Medicare Advantage Prescription Drug (MAPD) plans.
To qualify, beneficiaries generally must meet one of the following criteria:
• Have a Body Mass Index (BMI) of 35 or higher.
• Have a BMI of 27 or higher and at least one obesity-related medical condition, such as cardiovascular disease, hypertension, prediabetes, or other qualifying health conditions.
In addition, participants must be engaged in lifestyle interventions such as nutrition counseling, exercise programs, or weight-management coaching as recommended by their healthcare provider.
If you are already receiving GLP-1 medications for Medicare-covered conditions such as Type 2 diabetes you may continue receiving coverage under existing Medicare rules and may not need to use the Bridge Program.
Like those who benefitted from the $35 cap on insulin, the GL-1 Bridge Program makes these drugs affordable for eligible beneficiaries. Those who qualify will pay a flat copayment of just $50 per month for a 30-day supply of approved medications. This represents substantial savings compared to retail prices that often range from $900 to $1,300 per month.
Currently approved medications include Wegovy and Zepbound, with additional drugs potentially added as they become available.
But you need to know that unlike the $35 insulin cap, which does count towards your Part-D out-of-pocket prescription cap, the $50 monthly payment for GLP drugs does not count towards the annual out-of-pocket, which is $2,100 this year.
If you are on several prescription drugs, and will hit your out-of-pocket maximum, you might not want to consider this program.
Also know you cannot enroll yourself in the program. The enrollment process starts with your healthcare provider.
First, you must have an appointment with your PCP, who will review your BMI, medical history, and any obesity-related health conditions to determine whether you meet the program’s requirements.
If you qualify, your physician submits a Prior Authorization request directly to the Medicare GLP-1 Bridge Program. This request is sent to a centralized Medicare processing system rather than your Medicare drug plan.
Once approval is granted, your PCP writes a prescription for an approved medication. You then can then fill the prescription at a participating pharmacy and pay the $50 monthly copayment.
It is estimated that as many as 29 million to 30 million Medicare beneficiaries could meet the medical criteria for anti-obesity medications. It also means that getting in to see your PCP might become a challenge. As well as the time it might take for CMS to give it’s approval to your request. So if you are interested in the program I suggest you schedule your appointment now.
Important to note – Prior Authorization requests cannot be submitted by your PCP until after July 1, 2026.
The potential impact of the program is enormous.
The Medicare GLP-1 Bridge Program is currently scheduled to run through December 31, 2027. During that time, CMS will evaluate enrollment, costs, and health outcomes to determine whether broader Medicare coverage of obesity medications makes sense in the future.
For now, the program represents a significant shift in how Medicare approaches obesity treatment. By lowering costs and simplifying access through physician-directed enrollment, Medicare is giving millions of beneficiaries a new opportunity to address a chronic condition that affects both quality of life and long-term health.
The next Medicare 101 seminar will be June 19th @ 6pm. Followed by July 13 @ 6pm at our office at 603 Bay in TC. Call to reserve you seat.